Phase IB/II Study of Pasireotide, Everolimus and Selective Internal Radioembolization Therapy (SIRT) for Unresectable Neuroendocrine Hepatic Metastases

Trial Profile

Phase IB/II Study of Pasireotide, Everolimus and Selective Internal Radioembolization Therapy (SIRT) for Unresectable Neuroendocrine Hepatic Metastases

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs Everolimus (Primary) ; Pasireotide (Primary) ; Yttrium-90
  • Indications Intestinal cancer; Liver metastases; Neuroendocrine tumours; Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Nov 2017 Planned End Date changed from 1 Mar 2018 to 1 Mar 2019.
    • 20 Nov 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
    • 17 Nov 2016 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top